{"entity":{"id":"nct06490536","kind":"trial","name":"The Sagittarius Trial","aka":[],"tldr":"A phase 3 trial of fOLFOX (5-FU, leucovorin, oxaliplatin), capecitabine, leucovorin (folinic acid), fluorouracil (5-FU) and other drugs in colorectal cancer, run by IFOM ETS - The AIRC Institute of Molecular Oncology, now recruiting.","summary":"The Sagittarius Trial is a phase 3, randomised interventional study registered as NCT06490536 by IFOM ETS - The AIRC Institute of Molecular Oncology, with a registry enrolment figure of 700 participants, started 2024-10-22 and due to reach its primary completion in 2026-03-01. Interventions recorded: Oxaliplatin; Capecitabine; Folinic acid; Fluorouracil; Temozolomide; Irinotecan; Nivolumab; Ipilimumab; Trastuzumab; Pertuzumab; Panitumumab. Conditions listed: Colon Cancer Stage II; Colon Cancer Stage III. Primary outcome: 2-Year Recurrence-Free Survival (RFS). Sites: Germany, Italy, Spain. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06490536","url":"https://clinicaltrials.gov/study/NCT06490536"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","monoclonal-antibody","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["folfox","capecitabine","leucovorin","fluorouracil","temozolomide","folfiri","nivolumab","ipilimumab","trastuzumab","pertuzumab","panitumumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06490536","phase":"3","setting":"A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer Patients","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","enrolled":700,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06490536/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}